watson allergan > teva > schumer
https://knowledge.wharton.upenn.edu/article/why-teva-paid-40-5-billion-for-allergans-generic-business/
>On July 27, Israel’s Teva Pharmaceuticals acquired the global generic pharmaceuticals business of Dublin-headquartered Allergan in a $40.5 billion deal. The first obstacle to understanding the importance of this deal is the slew of superlatives around it.
this is the business model, create the problem and sell a remedy